185 related articles for article (PubMed ID: 31574507)
1. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
[TBL] [Abstract][Full Text] [Related]
2. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
3. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Peverelli E; Giardino E; Treppiedi D; Vitali E; Cambiaghi V; Locatelli M; Lasio GB; Spada A; Lania AG; Mantovani G
Endocrinology; 2014 Aug; 155(8):2932-41. PubMed ID: 24828612
[TBL] [Abstract][Full Text] [Related]
4. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
5. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
7. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
8. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
[TBL] [Abstract][Full Text] [Related]
9. beta 2-adrenergic receptor internalization, endosomal sorting, and plasma membrane recycling are regulated by rab GTPases.
Seachrist JL; Anborgh PH; Ferguson SS
J Biol Chem; 2000 Sep; 275(35):27221-8. PubMed ID: 10854436
[TBL] [Abstract][Full Text] [Related]
10. Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.
Vitali E; Cambiaghi V; Zerbi A; Carnaghi C; Colombo P; Peverelli E; Spada A; Mantovani G; Lania AG
Endocr Relat Cancer; 2016 Mar; 23(3):181-90. PubMed ID: 26733502
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.
Dicitore A; Saronni D; Gaudenzi G; Carra S; Cantone MC; Borghi MO; Persani L; Vitale G
J Endocrinol Invest; 2022 Jan; 45(1):29-41. PubMed ID: 34128215
[TBL] [Abstract][Full Text] [Related]
14. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
15. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
Acunzo J; Thirion S; Roche C; Saveanu A; Gunz G; Germanetti AL; Couderc B; Cohen R; Figarella-Branger D; Dufour H; Brue T; Enjalbert A; Barlier A
Cancer Res; 2008 Dec; 68(24):10163-70. PubMed ID: 19074883
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
18. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
[TBL] [Abstract][Full Text] [Related]
19. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
